Beyond Bispecifics: Novel Modalities Increase the Therapeutic Window & Durability Of Next-Generation TCEs

• New TCE designs are necessary to crack the code of solid-tumor TCEs and address relapsed/refractory heme malignancies
• Better biological data packages are necessary to design avidity-driven modalities
• CD3 affinity needs to be developed in the context of the modality with more thoughtful clinical dosing regimens

Speakers:

Paola Marcovecchio

Senior Principal Scientist

Pfizer